Prevention of Venous Thromboembolic Events After Gynecologic Surgery

• Published in: Obstetrics and gynecology (New York. 1953) Vol. 119; no. 1; pp. 155 - 167
• Main Authors: Clarke-Pearson, Daniel L, Abaid, Lisa N
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD The American College of Obstetricians and Gynecologists 01.01.2012; Lippincott Williams & Wilkins
• Subjects: Anesthesia - adverse effects; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Female; Gynecologic Surgical Procedures - adverse effects; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Postoperative Complications - prevention & control; Risk Factors; Venous Thromboembolism - etiology; Venous Thromboembolism - prevention & control; Vascular disease; Prevention; Gynecology; Cardiovascular disease; Thromboembolism; Vein; Obstetrics; Thrombosis; Embolism; Female genital diseases
• ISSN: 0029-7844; 1873-233X
• DOI: 10.1097/AOG.0b013e31823d389e

Venous thromboembolic events (deep vein thrombosis [DVT] and pulmonary embolism) are serious preventable complications associated with gynecologic surgery. Preoperative risk assessment of the individual patient will provide insight into the level of risk and the potential benefits of prophylaxis. Common risks include a history of venous thromboembolism, age, major surgery, cancer, use of oral contraceptives or hormone therapy, and obesity. Based on the presence of risk factors, the patient should be categorized into one of four risk groups and appropriate thromboprophylaxis prescribed. Randomized clinical trials in gynecologic surgery and general surgery have established the significant value of thromboprophylaxis. For moderate- and high-risk patients undergoing surgery for benign gynecologic conditions, low-dose unfractionated heparin, low molecular weight (LMW) heparins, intermittent pneumatic leg compression, and graded compression stockings all have demonstrated benefit. If using low-dose unfractionated heparin in high-risk patients, the heparin should be administered 5,000 units every 8 hours. Because DVT often begins in the perioperative period, it is important to initiate low-dose unfractionated heparin or administer the first LMW heparin dose either 2 hours preoperatively or 6 hours after the surgical procedure. Low molecular weight heparin has the advantage of being administered once daily but is more expensive than low-dose unfractionated heparin. In addition, LMW heparin has not been shown to be more effective and has similar risk of bleeding complications when compared with low-dose unfractionated heparin. In the very high-risk patient, a combination of two prophylactic methods may be advisable and continuing LMW heparin for 28 days postoperatively appears to be of added benefit.